Abcuro

Breakthrough Therapies for Autoimmune Diseases and Cancer

Newton, United States · Founded 2015 · $473.3M raised

Employees
51–200
Founded
2015
Business Model
B2B
Website
abcuro.com
Total Funding
$473.3M
Last Round
$66.0M Series DAug 2026
Rounds
6

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies targeting KLRG1 (Killer cell Lectin-like Receptor G1) for rare autoimmune diseases and cancers. Its lead candidate ulviprubart (ABC008) is in Phase 2/3 pivotal trials for Inclusion Body Myositis (IBM) and Phase 1 trials for T-Cell Large Granular Lymphocytic Leukemia (T-LGLL). The company has raised over $200M in Series C financing led by New Enterprise Associates with participation from Sanofi Ventures, RA Capital, and Bain Capital Life Sciences.

Summary

Abcuro is a Biotech company based in Newton, United States, founded in 2015. It has raised $473.3M in total across 6 rounds, most recently a $66.0M Series D round in Aug 2026. Investors include Bain Capital Life Sciences, Redmile Group and Sanofi Ventures.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series DSeries DAug 2026
$66.0M

Sign up to see all 6 events

Funding: Seed through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Abcuro on Indexed.vc
<a href="https://indexed.vc/companies/abcuro"><img src="https://indexed.vc/api/badge/company/abcuro" alt="Abcuro on Indexed.vc" width="260" height="76" /></a>